Drug Trial Radar · NCT04709536
A Study of IBI306 in Participants With Hypercholesterolemia
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
306
Actual
Start
Feb 9, 2021
Primary completion
Nov 9, 2021
Study completion Jan 28, 2022
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed for multi-center, double-blind, randomized, placebo-controlled phase III trial to evaluate the safety and tolerability of subcutaneous injection of IBI306 in hypercholesterolemia patients.
Conditions
- Hypercholesterolemia
Interventions
IBI306Drug
Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
PlaceboDrug
Recombinant humanized Anti- PCSK9 monoclonal antibody, administered SC from BL to week 24
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 12Time frame: Baseline to week12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.